{"id":"https://openalex.org/W2467053862","doi":"https://doi.org/10.1182/blood.v124.21.5196.5196","title":"In Vitro and in Vivo Quantification of Exportin-1 (XPO1) Occupancy By the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor in Multiple Myeloma, Acute Myeloid Leukemia, and Healthy PBMCs","display_name":"In Vitro and in Vivo Quantification of Exportin-1 (XPO1) Occupancy By the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor in Multiple Myeloma, Acute Myeloid Leukemia, and Healthy PBMCs","publication_year":2014,"publication_date":"2014-12-06","ids":{"openalex":"https://openalex.org/W2467053862","doi":"https://doi.org/10.1182/blood.v124.21.5196.5196","mag":"2467053862"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v124.21.5196.5196","doi":"https://doi.org/10.1182/blood.v124.21.5196.5196","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.5196.5196","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5084986364","display_name":"Marsha L. Crochiere","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marsha Crochiere","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050484646","display_name":"Boris Klebanov","orcid":"https://orcid.org/0000-0002-6969-6582","observed_orcids":["https://orcid.org/0000-0002-6969-6582"]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Boris Klebanov","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067532930","display_name":"Erkan Baloglu","orcid":"https://orcid.org/0000-0002-4106-732X","observed_orcids":["https://orcid.org/0000-0002-4106-732X"]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erkan Baloglu","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062925432","display_name":"Ori Kalid","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ori Kalid","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061973648","display_name":"Trinayan Kashyap","orcid":"https://orcid.org/0000-0002-8784-5641","observed_orcids":["https://orcid.org/0000-0002-8784-5641"]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Trinayan Kashyap","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038643879","display_name":"William T. Senapedis","orcid":"https://orcid.org/0009-0004-1566-2733","observed_orcids":["https://orcid.org/0009-0004-1566-2733"]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Senapedis","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045995178","display_name":"Diego del Alamo","orcid":"https://orcid.org/0000-0003-1757-9971","observed_orcids":["https://orcid.org/0000-0003-1757-9971"]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diego del Alamo","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083579907","display_name":"Tami Rashal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tami Rashal","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101668176","display_name":"Sharon Tamir","orcid":"https://orcid.org/0000-0003-0820-1184","observed_orcids":["https://orcid.org/0000-0003-0820-1184"]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sharon Tamir","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017267359","display_name":"Dilara McCauley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dilara McCauley","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108576096","display_name":"Robert O. Carlson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Carlson","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049400849","display_name":"Michael Robert Savona","orcid":"https://orcid.org/0000-0003-3763-5504","observed_orcids":["https://orcid.org/0000-0003-3763-5504"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Savona","raw_affiliation_strings":["Vanderbilt University School of Medicine, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University School of Medicine, Nashville, TN","institution_ids":["https://openalex.org/I200719446"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112906141","display_name":"Michael G. Kauffman","orcid":"https://orcid.org/0000-0001-5643-0200","observed_orcids":["https://orcid.org/0000-0001-5643-0200"]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Kauffman","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051352882","display_name":"Sharon Shacham","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sharon Shacham","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5057755017","display_name":"Yosef Landesman","orcid":"https://orcid.org/0000-0001-5542-5098","observed_orcids":["https://orcid.org/0000-0001-5542-5098"]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yosef Landesman","raw_affiliation_strings":["Karyopharm Therapeutics, Inc, Newton, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics, Inc, Newton, MA","institution_ids":["https://openalex.org/I4210152529"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.23084989,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"124","issue":"21","first_page":"5196","last_page":"5196"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11841","display_name":"Nuclear Structure and Function","score":0.8964999914169312,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11841","display_name":"Nuclear Structure and Function","score":0.8964999914169312,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.07530000060796738,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10492","display_name":"Microtubule and mitosis dynamics","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/selinexor","display_name":"selinexor","score":0.9520000219345093},{"id":"https://openalex.org/keywords/xpo1","display_name":"CRM1","score":0.8460000157356262},{"id":"https://openalex.org/keywords/binding-assays","display_name":"binding assays","score":0.4790000021457672},{"id":"https://openalex.org/keywords/peripheral-blood-mononuclear-cells","display_name":"peripheral blood mononuclear cells","score":0.7350000143051147},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9739999771118164},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":1.0},{"id":"https://openalex.org/keywords/pharmacodynamic-markers","display_name":"pharmacodynamic biomarkers","score":0.5519999861717224},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.4860000014305115},{"id":"https://openalex.org/keywords/binding-kinetics","display_name":"binding kinetics","score":0.6460000276565552},{"id":"https://openalex.org/keywords/tumor-suppressor-proteins","display_name":"tumor suppressor proteins","score":0.5189999938011169},{"id":"https://openalex.org/keywords/p53","display_name":"p53","score":0.5379999876022339},{"id":"https://openalex.org/keywords/foxo","display_name":"FOXO","score":0.6660000085830688}],"concepts":[{"id":"https://openalex.org/C204628709","wikidata":"https://www.wikidata.org/wiki/Q864854","display_name":"Biotinylation","level":2,"score":0.8145982027053833},{"id":"https://openalex.org/C54757728","wikidata":"https://www.wikidata.org/wiki/Q3511067","display_name":"Nuclear export signal","level":4,"score":0.5254230499267578},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4614068567752838},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.45597800612449646},{"id":"https://openalex.org/C137061746","wikidata":"https://www.wikidata.org/wiki/Q736033","display_name":"Peripheral blood mononuclear cell","level":3,"score":0.423711359500885},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.4211042523384094},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.41630226373672485},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.40855857729911804},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39981165528297424},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.3109583258628845},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.2961888611316681},{"id":"https://openalex.org/C2780114586","wikidata":"https://www.wikidata.org/wiki/Q40260","display_name":"Cell nucleus","level":3,"score":0.1815827190876007},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.13052842020988464},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.1108979880809784}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v124.21.5196.5196","doi":"https://doi.org/10.1182/blood.v124.21.5196.5196","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.5196.5196","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2191662205","https://openalex.org/W3085508826","https://openalex.org/W4379052430","https://openalex.org/W2771082628","https://openalex.org/W2979691623","https://openalex.org/W2210730941","https://openalex.org/W2588237868","https://openalex.org/W3034857964","https://openalex.org/W2980036644","https://openalex.org/W7212949060"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"SINE":[2,34,70,150,190,208,222,298],"are":[3,453],"a":[4,16,125,393,423,460],"family":[5],"of":[6,30,45,62,104,119,132,142,149,171,182,244,274,297,396,531,550],"small":[7],"molecules":[8],"that":[9,110,128,181,218,315,434],"selectively":[10],"inhibit":[11],"nuclear":[12,41],"export":[13],"by":[14,242,272],"forming":[15],"slowly":[17],"reversible":[18],"covalent":[19],"bond":[20],"with":[21,98,174,207,213,239,248,253,268,292,310,319,373,392,444,467,472],"Cysteine":[22],"528":[23],"(Cys528)":[24],"in":[25,59,73,96,101,107,135,167,185,194,233,282,326,330,334,339,365,412,447,470],"the":[26,147,168],"cargo":[27],"binding":[28,35,126,148,191,280,431],"pocket":[29],"Exportin":[31],"1":[32],"(XPO1/CRM1).":[33],"to":[36,39,114,123,151,165,177,180,192,211,225,265,400,416,428,432,438,455],"XPO1":[37,105,133,173,193,217,302,317,355,363,381,410,433,463],"leads":[38],"forced":[40],"retention":[42],"and":[43,56,77,84,163,199,228,260,287,300,336,425,449,474],"activation":[44],"major":[46],"tumor":[47],"suppressor":[48],"proteins":[49],"(TSPs)":[50],"such":[51],"as":[52],"p53,":[53],"FOXO,":[54],"pRB":[55],"IkB,":[57],"resulting":[58],"selective":[60],"death":[61],"cancer":[63,196],"cells.":[64,341],"Selinexor":[65],"is":[66,459],"an":[67,528,547],"orally":[68],"bioavailable":[69],"compound":[71],"currently":[72],"human":[74,203,346],"phase":[75],"I":[76],"II":[78],"clinical":[79,450],"trials":[80],"for":[81,112,246,403,414],"advanced":[82],"hematological":[83,475],"solid":[85,473],"cancers.":[86],"Oral":[87],"selinexor":[88,320,397,430,446],"demonstrates":[89],"maximal":[90],"pharmacokinetic":[91],"exposure":[92,441],"at":[93,323,357,385],"1-2":[94],"hours":[95,109,371,405],"humans":[97],"associated":[99],"increases":[100],"pharmacodynamic":[102],"markers":[103],"inhibition":[106],"2-4":[108],"last":[111],"up":[113,415],"48":[115],"hours.":[116,418],"The":[117],"goal":[118],"this":[120],"study":[121],"was":[122,157,303,321,367,383],"develop":[124],"assay":[127,427],"would":[129],"enable":[130],"quantification":[131],"occupancy":[134,318,343,356,364,382,411,464],"PBMCs":[136,200,245,347,413],"from":[137,201,306,349,398],"patients":[138,471],"following":[139,442],"oral":[140,445],"administration":[141],"selinexor.":[143],"Methods:":[144],"To":[145,188,277],"measure":[146,189,429],"XPO1,":[152],"biotinylated":[153,214,226,249,254,311],"leptomycin":[154],"B":[155],"(LMB)":[156],"utilized.":[158],"Biotinylated":[159],"LMB":[160,184,227],"binds":[161,224],"covalently":[162],"irreversibly":[164],"Cys528":[166],"cargo-binding":[169],"site":[170],"free":[172],"activity":[175],"confirmed":[176],"be":[178,230,436],"similar":[179],"unmodified":[183],"cytotoxicity":[186],"assays.":[187],"vitro,":[195,283],"cell":[197,307],"lines":[198],"normal":[202],"donors":[204],"were":[205,237,257,263,290],"treated":[206,238,291,309,391],"compounds":[209,299],"prior":[210],"treatment":[212,247,372,443],"LMB.":[215,250,312],"Any":[216],"did":[219],"not":[220],"bind":[221],"instead":[223],"can":[229,435],"quantified.":[231],"In":[232,360],"vivo":[234],"studies,":[235],"mice":[236],"selinexor,":[240,378],"followed":[241,271],"collection":[243],"After":[251],"incubation":[252],"LMB,":[255],"cells":[256,289],"harvested,":[258],"lysed,":[259],"protein":[261],"lysates":[262,308],"subjected":[264],"pull-down":[266],"experiments":[267,344],"streptavidin-conjugated":[269],"beads":[270],"immunoanalysis":[273],"XPO1.":[275],"Results:":[276],"evaluate":[278,439],"selinexor-XPO1":[279],"kinetics":[281],"MM.1S,":[284,327],"AML2,":[285,331],"AML3,":[286,335],"HEL":[288,340],"0":[293],"-":[294],"10":[295,401],"\u00b5M":[296,325,329,333,338],"unbound":[301],"pulled":[304],"down":[305],"Immunoanalysis":[313],"showed":[314,353],"50%":[316,354,362],"achieved":[322,368,384],"0.07":[324],"0.1":[328],"0.03":[332],"0.12":[337],"Selinexor-XPO1":[342],"using":[345],"isolated":[348],"donor":[350],"whole":[351],"blood":[352],"0.05":[358],"\u00b5M.":[359],"mice,":[361],"PMBCs":[366],"after":[369],"4":[370],"1.2":[374],"mg/kg":[375,387,402],"(3.6":[376],"mg/m2)":[377],"while":[379],"90%":[380],"8.1":[386],"(24.3":[388],"mg/m2).":[389],"Mice":[390],"single":[394],"dose":[395,408],"1.5":[399],"4-96":[404],"revealed":[406],"sustained,":[407],"dependent":[409],"72":[417],"Conclusions:":[419],"We":[420],"have":[421],"developed":[422],"sensitive":[424],"robust":[426],"used":[437],"drug":[440],"preclinical":[448],"studies.":[451],"Studies":[452],"ongoing":[454],"determine":[456],"whether":[457],"there":[458],"correlation":[461],"between":[462],"(pharmacodynamics":[465],"measurement)":[466],"disease":[468],"response":[469],"malignancies.":[476],"Disclosures":[477],"Crochiere:":[478],"Karyopharm:":[479],"Employment.":[480,483,485,488,491,493,496,499,501,509,560],"Klebanov:Karyopharm":[481],"Therpeutics:":[482],"Baloglu:Karyopharm:":[484],"Kalid:Karyopharm":[486],"Therapeutics:":[487,490,498,503,508,559],"Kashyap:Karyopharm":[489],"Senapedis:Karyopharm:":[492],"del":[494],"Alamo:Karyopharm:":[495],"Rashal:Karyopharm":[497],"Tamir:Karyopharm:":[500],"McCauley:Karyopharm":[502],"Employment,":[504,523,542],"Equity":[505,512,524,543],"Ownership.":[506],"Carlson:Karyopharm":[507],"Savona:Karyopharm:":[510],"Consultancy,":[511],"Ownership;":[513],"Gilead:":[514],"Consultancy;":[515,517],"Incyte:":[516],"Celgene:":[518],"Consultancy.":[519],"Kauffman:Karyopharm":[520],"Therapeutics,":[521,540],"Inc:":[522,541],"Ownership,":[525,544],"Membership":[526,545],"on":[527,546],"entity's":[529,548],"Board":[530,549],"Directors":[532,551],"or":[533,552],"advisory":[534,553],"committees,":[535,554],"Patents":[536,555],"&":[537,556],"Royalties.":[538,557],"Shacham:Karyopharm":[539],"Landesman:Karyopharm":[558]},"counts_by_year":[],"updated_date":"2026-10-02T10:15:12.560889","created_date":"2016-07-22T00:00:00"}